R & D projects (Q3312831): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: translated_label) |
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
||
Property / contained in NUTS | |||
Property / contained in NUTS: Germersheim / rank | |||
Normal rank |
Revision as of 23:12, 24 October 2021
Project Q3312831 in Germany
Language | Label | Description | Also known as |
---|---|---|---|
English | R & D projects |
Project Q3312831 in Germany |
Statements
516,561.12 Euro
0 references
1,067,495.6 Euro
0 references
48.39 percent
0 references
17 March 2020
0 references
31 March 2022
0 references
HWI pharma services GmbH
0 references
76761
0 references
Mit der innovativen Screening- und Technologie-Plattform lassen sich parenterale (sterile) Arzneimittel mit schwerlöslichen chemischen und biologischen Wirkstoffen mittels Nanotechnologie schneller, effizienter und kostengünstiger entwickeln und herstellen. (German)
0 references
With the innovative screening and technology platform, parenteral (sterile) medicines with insoluble chemical and biological agents can be developed and manufactured using nanotechnology faster, more efficiently and cost-effectively. (English)
25 October 2021
0 references
Germersheim
0 references
Identifiers
DE_TEMPORARY_15618
0 references